IMV Tests Drug with Breast Cancer

Dartmouth-based drug discovery company IMV has announced that its lead compound, known as maveropepimut-S, will be trialed in patients with hormone receptor positive/HER2-negative breast cancer.
In a statement, the company said these tumors represent an unmet clinical need with relatively poor responses to preliminary hormonal treatment. The investigator-initiated clinical study will be